372 related articles for article (PubMed ID: 34045662)
1. Current challenges and unmet medical needs in myelodysplastic syndromes.
Platzbecker U; Kubasch AS; Homer-Bouthiette C; Prebet T
Leukemia; 2021 Aug; 35(8):2182-2198. PubMed ID: 34045662
[TBL] [Abstract][Full Text] [Related]
2. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with lower-risk myelodysplastic syndromes.
Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging strategies for management of myelodysplastic syndromes.
Saygin C; Carraway HE
Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
[TBL] [Abstract][Full Text] [Related]
5. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
6. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
7. Raising the bar for lower-risk myelodysplastic syndromes.
Venugopal S; Sekeres MA
Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
Scalzulli E; Pepe S; Colafigli G; Breccia M
Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in the treatment of myelodysplastic syndromes].
Gelsi-Boyer V; Vey N
Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
[TBL] [Abstract][Full Text] [Related]
10. Educational and Emotional Needs of Patients with Myelodysplastic Syndromes: An AI Analysis of Multi-Country Social Media.
Frank PP; Lu MXE; Sasse EC
Adv Ther; 2023 Jan; 40(1):159-173. PubMed ID: 36136244
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions.
Navada SC; Silverman LR
Curr Hematol Malig Rep; 2011 Mar; 6(1):5-12. PubMed ID: 21153773
[TBL] [Abstract][Full Text] [Related]
12. Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis.
Booth A; Bell T; Halhol S; Pan S; Welch V; Merinopoulou E; Lambrelli D; Cox A
J Med Internet Res; 2019 Nov; 21(11):e14285. PubMed ID: 31755871
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
Dan C; Chi J; Wang L
Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
[TBL] [Abstract][Full Text] [Related]
16. Overview of the Management of Higher-Risk Myelodysplastic Syndromes.
Singh A; Carraway HE
Cancer J; 2023 May-Jun 01; 29(3):160-167. PubMed ID: 37195772
[TBL] [Abstract][Full Text] [Related]
17. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
18. Childhood myelodysplastic syndrome.
Chatterjee T; Choudhry VP
Indian J Pediatr; 2013 Sep; 80(9):764-71. PubMed ID: 23912822
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM; Faltas B; Douglas Smith B; Gore S
J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
[TBL] [Abstract][Full Text] [Related]
20. Strategies for achieving transfusion independence in myelodysplastic syndromes.
Thomas ML
Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]